U.S. regulators approved a label expansion for Novo Nordisk’s obesity drug Wegovy to tout its benefits for the heart, a move that could boost demand and insurance coverage for the already highly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback